Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

Neuralstem, Inc. Exhibit
EX-99.01 2 exh_9901.htm PRESS RELEASE EdgarFilingExhibit 99.01Neuralstem Reports Year End 2017 Fiscal Results and Business Update – Neuralstem Releases Full Data Set for NSI-189 MDD Trial Showing Patient Rated Outcome and Cognitive Benefits - Nature Medicine Paper Demonstrates Benefit of NSI-566 on Paralysis in Non-Human Primates GERMANTOWN,…
To view the full exhibit click here

About Neuralstem, Inc. (NASDAQ:CUR)

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.